Generate Biomedicines (NASDAQ:GENB) Hits New 1-Year High – What’s Next?

Generate Biomedicines Inc (NASDAQ:GENB)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $17.98 and last traded at $16.91, with a volume of 1704246 shares traded. The stock had previously closed at $16.47.

Analyst Upgrades and Downgrades

GENB has been the topic of several recent research reports. Piper Sandler began coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 target price for the company. Morgan Stanley upped their target price on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Guggenheim began coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Wall Street Zen cut shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Generate Biomedicines currently has an average rating of “Moderate Buy” and a consensus target price of $25.40.

Generate Biomedicines Price Performance

The company’s 50-day moving average price is $13.85.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.